Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 08, 2026 1 hour, 41 minutes ago
Medical News: A widely used diabetes drug may be quietly interfering with how patients sleep, raising fresh concerns about its broader effects on health. New research suggests that Metformin, a first-line treatment for type 2 diabetes, could alter critical stages of sleep - especially in patients who also suffer from sleep apnea.
Common diabetes drug found to reduce critical REM sleep in patients with sleep apnea
Growing Overlap Between Diabetes and Sleep Disorders
Type 2 diabetes and obstructive sleep apnea (OSA) are increasingly seen as interconnected conditions. Patients with both often experience poor sleep quality, fatigue, and metabolic complications. Researchers have long known that disrupted sleep can worsen blood sugar control, but the role of medications in this cycle has remained less clear.
The new study explored how Metformin affects “sleep architecture” - the structure and balance of different sleep stages. These include REM sleep, which is vital for memory and brain function, and deep sleep (N3), which supports physical recovery and hormone regulation.
How the Study Was Conducted
Researchers analyzed overnight sleep studies from patients diagnosed with both type 2 diabetes and symptoms of sleep apnea, including snoring and daytime fatigue. These sleep studies, known as polysomnograms, measured brain activity, breathing patterns, and sleep stages in detail.
The research was conducted by scientists from the Department of Medical Education, School of Medicine, California University of Science and Medicine (CUSM), Colton, California, USA.
A total of 51 patients were included, with 29 taking Metformin and 22 using other diabetes treatments. The team compared how long patients spent in each sleep stage and analyzed factors such as age, body weight, sex, and smoking history.
Key Findings That Raise Concerns
The most striking finding was a consistent reduction in REM sleep among patients taking Metformin. On average, these individuals spent significantly less time in REM sleep compared to those on alternative treatments.
This effect was especially pronounced in non-obese patients. Among individuals with a body mass index below 30, those on Metformin had notably shorter REM sleep durations. In contrast, obese patients showed no statistically significant difference, although trends still suggested reduced REM.
Interestingly, deep sleep (N3) did not differ significantly between groups. However, overall patterns hinted that both REM and N3 sleep may be lower in Metformin users.
This
Medical News report highlights that these changes were not influenced by sex or smoking habits, suggesting the drug itself may play a central role.
Why REM Sleep Matters More Than You Think
REM sleep is not just about dreaming. It is crucial for memory consolidation, emotional regulation, and brain r
epair. Reduced REM sleep has been linked to cognitive decline, poor learning ability, and even increased risk of neurological conditions.
The findings are particularly concerning for older adults. Aging already reduces REM sleep naturally, and adding another factor that further suppresses it could amplify risks related to memory loss and reduced quality of life.
A Complex Relationship Between Treatment and Health
Metformin is known for improving insulin sensitivity and lowering blood sugar, but this study suggests it may also influence brain activity during sleep. Researchers believe these changes could potentially contribute to worsening insulin resistance over time, creating a paradox where treatment may indirectly affect the condition it aims to manage.
At the same time, the study emphasizes that these findings are observational. The sample size was relatively small, and other factors - such as overall blood sugar control and additional medications - could also play a role.
Conclusion
The study provides compelling early evidence that Metformin may alter sleep patterns, particularly by reducing REM sleep in patients with type 2 diabetes and sleep apnea. This could have important implications for cognitive health, metabolic control, and overall well-being, especially in aging populations. However, the findings should not prompt patients to stop medication without medical advice. Larger and more detailed studies are urgently needed to confirm these results, understand the underlying mechanisms, and determine whether adjustments in treatment strategies are necessary to protect both metabolic and sleep health.
The study findings were published in the peer reviewed journal: Diabetology.
https://www.mdpi.com/2673-4540/7/4/75
For the latest on the possible negative health effects from metformin use, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/diabetes
https://www.thailandmedical.news/articles/med-news
Share
Tweet
Share
